- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- NACDS RxImpact shines spotlight on pharmacists' increasing role in delivery of healthcare services
- Study from NCPA sheds new light on med synchronization programs
PHOENIX — Specialty pharmacy provider The Apothecary Shops has inked a deal with Pfizer to distribute a new drug for treating kidney cancer.
The specialty provider announced Wednesday that Pfizer had granted it distribution rights for Inlyta (axitinib), which the Food and Drug Administration approved on Jan. 27 for advanced renal cell carcinoma in patients who have failed one systemic therapy.
"The Apothecary Shops is excited to be included in the limited network of pharmacies managing Inlyta," The Apothecary Shops president Keith Cook said. "We have a first-class oncology team, and this announcement certainly reinforces our strong position in the oncology market."